Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NeoProgen
AddedFeb 16, 2024
UpdatedJun 18, 2026
NeoProgen

NeoProgen

Seed

NeoProgen, founded in 2018, is a Maryland-based biotech firm specializing in neonatal cardiac therapy.

Founded
2018
Overview
Compare
Fundraising
Employees

NeoProgen, founded in 2018, is a Maryland-based biotech firm specializing in neonatal cardiac therapy. The company focuses on advancing neonatal cardiac progenitor cells to develop innovative treatments for heart conditions. Their mission is to revolutionize cardiac care through cutting-edge biotechnology.

NeoProgen has made significant strides in cardiac therapy, contributing to advancements in neonatal cardiac care. Their pioneering work in biotechnology has positioned them as a leader in the field, impacting patient outcomes and advancing medical research.

NeoProgen - Similar Companies

Secretome Therapeutics logo

Secretome Therapeutics

Ventrinova logo

Ventrinova

Noveome Biotherapeutics logo

Noveome Biotherapeutics

noveome.com

Progenerative Medical logo

Progenerative Medical

progenerative.com

BioCardia logo

BioCardia

Nephrogen logo

Nephrogen

Novo Biosciences logo

Novo Biosciences

Cardiovate logo

Cardiovate

Neuraly logo

Neuraly

neuralymed.com

Ne Plus logo

Ne Plus

NeyroblastGX logo

NeyroblastGX

neyroblastgx.com

Neonc Technologies logo

Neonc Technologies

neonctech.com

Platelet BioGenesis logo

Platelet BioGenesis

Cardurion Pharmaceuticals logo

Cardurion Pharmaceuticals

AlphaStem logo

AlphaStem

alpha-stim.com

NeoProgen - Quick Facts

Who are NeoProgen's competitors?

Companies similar to NeoProgen include Secretome Therapeutics, Ventrinova, Noveome Biotherapeutics and Progenerative Medical.

When was NeoProgen founded?

NeoProgen was founded in 2018.

When was NeoProgen's last funding round?

NeoProgen's most recent funding round was for $1.5M (USD) in October 2019.

How much has NeoProgen raised to-date?

As of Oct 17, 2019, NeoProgen has raised a total of $1.5M (USD).

How many employees does NeoProgen have?

NeoProgen has 6 employees as of Feb 4, 2024.

NeoProgen - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cardiac Therapy
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research